-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PROTACs enhance TILs therapy
Tumor-infiltrating lymphocytes (TILs) are a heterogeneous population of T cells that recognize a variety of endogenous tumor antigens but may develop an exhausted phenotype in the tumor microenvironment
CRISPR Knockout PD-1 (Mol Ther Oncolytics.
clinical research
Advanced solid tumors (platinum-resistant ovarian cancer, endometrial cancer, cervical cancer) starting November 12, 2021
NCT05107739 A Study of DeTIL-0255 in Adults With Advanced Malignancies
ASCO Poster
A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies.
Antibody drug enhances NK cell therapy
Natural killer cells (NKs) are effector cells of the innate immune system that mount cytotoxic and effector responses to stress cells such as viral infections and tumor cytokines
Celularity (CELU), headquartered in Florham Park, spun off from Celgene Cell Therapy in May 2016, raised $45 million in Series A financing in 2017, $21 million in Series B financing, and $100 million in Series B-1 financing in 2019.
Clinical Trials
HER2 antibody (trastuzumab) and other combination therapy for HER2+ solid tumors (NCT05207722, phase 1/2 clinical, 52 patients planned to be recruited)
References
www.
https://celularity.
ASCO Abstract: https://ascopubs.
Christopher Aled Chamberlain et al, Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy.
